These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22290786)

  • 1. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments.
    Dore DD; Turnbull BR; Seeger JD
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):415-9. PubMed ID: 22290786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States.
    Krishnarajah G; Davis EJ; Fan Y; Standaert BA; Buikema AR
    Vaccine; 2012 May; 30(24):3717-22. PubMed ID: 22214886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine.
    ;
    Pediatrics; 2009 May; 123(5):1412-20. PubMed ID: 19332437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule.
    Buttery JP; Lambert SB; Grimwood K; Nissen MD; Field EJ; Macartney KK; Akikusa JD; Kelly JJ; Kirkwood CD
    Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S25-9. PubMed ID: 21183837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations.
    Hoffman V; Everage NJ; Quinlan SC; Skerry K; Esposito D; Praet N; Rosillon D; Holick CN; Dore DD
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1465-1469. PubMed ID: 27623759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jun; 59(22):687-8. PubMed ID: 20535093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoption of rotavirus vaccine by U.S. physicians: progress and challenges.
    O'Leary ST; Parashar UD; Crane LA; Allison MA; Stokley S; Beaty BL; Brtnikova M; Hurley LP; Kempe A
    Am J Prev Med; 2013 Jan; 44(1):56-62. PubMed ID: 23253650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of history of intussusception as a contraindication for rotavirus vaccination.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(41):1427. PubMed ID: 22012117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatrics; 2010 Feb; 125(2):e208-13. PubMed ID: 20100757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011.
    Payne DC; Boom JA; Staat MA; Edwards KM; Szilagyi PG; Klein EJ; Selvarangan R; Azimi PH; Harrison C; Moffatt M; Johnston SH; Sahni LC; Baker CJ; Rench MA; Donauer S; McNeal M; Chappell J; Weinberg GA; Tasslimi A; Tate JE; Wikswo M; Curns AT; Sulemana I; Mijatovic-Rustempasic S; Esona MD; Bowen MD; Gentsch JR; Parashar UD
    Clin Infect Dis; 2013 Jul; 57(1):13-20. PubMed ID: 23487388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants.
    Shui IM; Baggs J; Patel M; Parashar UD; Rett M; Belongia EA; Hambidge SJ; Glanz JM; Klein NP; Weintraub E
    JAMA; 2012 Feb; 307(6):598-604. PubMed ID: 22318281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotavirus vaccination compliance and completion in a Medicaid infant population.
    Krishnarajah G; Landsman-Blumberg P; Eynullayeva E
    Vaccine; 2015 Jan; 33(3):479-86. PubMed ID: 24962753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.
    Boom JA; Tate JE; Sahni LC; Rench MA; Hull JJ; Gentsch JR; Patel MM; Baker CJ; Parashar UD
    Pediatrics; 2010 Feb; 125(2):e199-207. PubMed ID: 20083525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.
    Bégué RE; Perrin K
    Pediatrics; 2010 Jul; 126(1):e40-5. PubMed ID: 20587671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of monovalent and pentavalent rotavirus vaccine.
    Cortese MM; Immergluck LC; Held M; Jain S; Chan T; Grizas AP; Khizer S; Barrett C; Quaye O; Mijatovic-Rustempasic S; Gautam R; Bowen MD; Moore J; Tate JE; Parashar UD; Vázquez M
    Pediatrics; 2013 Jul; 132(1):e25-33. PubMed ID: 23776114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of RV1 and RV5 vaccines administered in standard and interchangeable mixed schedules: a randomized, double-blind, non-inferiority clinical trial in Mexican infants.
    Macías-Parra M; Vidal-Vázquez P; Reyna-Figueroa J; Rodríguez-Weber MÁ; Moreno-Macías H; Hernández-Benavides I; Fortes-Gutiérrez S; Richardson VL; Vázquez-Cárdenas P
    Front Public Health; 2024; 12():1356932. PubMed ID: 38463163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.
    Vesikari T; Karvonen A; Ferrante SA; Kuter BJ; Ciarlet M
    Pediatr Infect Dis J; 2010 Oct; 29(10):957-63. PubMed ID: 20442684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk.
    Kuehn BM
    JAMA; 2010 Jul; 304(1):30-1. PubMed ID: 20606142
    [No Abstract]   [Full Text] [Related]  

  • 20. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua.
    Mast TC; Khawaja S; Espinoza F; Paniagua M; Del Carmen LP; Cardellino A; Sánchez E
    Pediatr Infect Dis J; 2011 Nov; 30(11):e209-15. PubMed ID: 21768920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.